Volume 17, Number 3—March 2011
Escherichia coli O157 Infection and Secondary Spread, Scotland, 1999–2008
Highlight and copy the desired format.
|EID||Locking ME, Pollock K, Allison LJ, Rae L, Hanson MF, Cowden JM, et al. Escherichia coli O157 Infection and Secondary Spread, Scotland, 1999–2008. Emerg Infect Dis. 2011;17(3):524-527. https://dx.doi.org/10.3201/eid1703.100167|
|AMA||Locking ME, Pollock K, Allison LJ, et al. Escherichia coli O157 Infection and Secondary Spread, Scotland, 1999–2008. Emerging Infectious Diseases. 2011;17(3):524-527. doi:10.3201/eid1703.100167.|
|APA||Locking, M. E., Pollock, K., Allison, L. J., Rae, L., Hanson, M. F., & Cowden, J. M. (2011). Escherichia coli O157 Infection and Secondary Spread, Scotland, 1999–2008. Emerging Infectious Diseases, 17(3), 524-527. https://dx.doi.org/10.3201/eid1703.100167.|
To determine the proportion of Escherichia coli O157 cases in Scotland attributable to secondary spread, we analyzed data obtained through entire-population enhanced surveillance. We identified 11% of cases as secondary. Secondary cases in single households were younger than secondary cases in outbreaks affecting >1 household and had similar risk for hemolytic uremic syndrome.
Escherichia coli O157 remains a substantial public health challenge worldwide, particularly because of its association with hemolytic uremic syndrome (HUS) (1,2). The low infectious dose (3) exacerbates its potential to cause secondary spread and large outbreaks (4–10). Most published information about secondary spread derives from outbreaks (7,9–12) or from subgroups or settings not necessarily generalizable to whole populations (4,11). Rates of secondary cases range from 4% to 16% (4,9).
Associations with increased transmission include presence of siblings, young age of persons with primary or potential secondary cases (4,10,11), and waterborne compared with foodborne transmission in outbreaks (12). Scotland consistently reports higher rates of E. coli O157 infection than many other countries (Figure 1); E. coli O157 was identified in 81% of HUS cases (13). Although large outbreaks have occurred (7,8), most infections in Scotland are apparently sporadic (14) (Figure 2).
In 1999, Health Protection Scotland (HPS), in close collaboration with the Scottish E. coli O157/VTEC Reference Laboratory (Edinburgh, Scotland), established enhanced surveillance of E. coli O157 covering the entire population. HPS defines a case as a single-person infection episode with laboratory confirmation of infection as either culture positive or serum positive for E. coli O157. The term case refers to symptomatic and asymptomatic persons, i.e., patients and nonpatients.
HPS compiles standardized datasets for all cases, integrating microbiologic, epidemiologic, demographic, and exposure data; datasets include direct clinical reports of HUS under enhanced surveillance of thrombotic microangiopathies since 2003 (13) and detailed symptom descriptions since 2004. Secondary cases are defined as those symptomatic cases from whose onset date and an assumed incubation period (<14 days) we can infer that contact with a confirmed case was more likely than any other exposure to be the source of infection, and whose onset was >2 days after onset in the contact case. Cases having onset within 2 days after onset in a contact case are defined as co-primaries.
HPS surveillance systems collect information about general outbreaks, i.e., those affecting members of >1 household or residents of an institution. Other cases are therefore either sporadic or occur among members of a single household. For ease of comprehension, we refer to cases in general outbreaks as outbreak cases and cases or clusters restricted to a single household as sporadic cases, irrespective of whether they are secondary or primary cases. We analyzed data for all cases reported to HPS during 1999–2008 using χ2 and Mann-Whitney tests and considered p<0.05 as significant.
From January 1, 1999, through December 31, 2008, a total of 2,228 E. coli O157 cases were reported to HPS (mean 223 annually); the mean annual incidence rate was 4.4 cases per 100,000 population (Table 1; Figure 1). Ages of the 2,228 cases ranged from 4 months to 97 years (median 21 years). A minority of all cases (202/2,228 [9%]) were asymptomatic, in similar proportions annually (p = 0.44) (Table 1). All 1,118 cases reported 2004–2008 provided symptom details; 660 (59%) had bloody diarrhea. Varying proportions of cases each year were hospitalized (mean 41%; p<0.005) or had illness progressing to HUS (196/2,228; mean 9%; p = 0.03) (Table 1). HUS occurred more often in cases reporting bloody diarrhea than nonbloody diarrhea (14% vs. 3%, p<0.0005), suggesting that bloody diarrhea may be a better predictor of progression to HUS than was previously apparent in Scotland.
Secondary cases constituted 246/2,026 (12%) of the symptomatic cases (11% of all cases), with proportions varying annually (range 4%–20%; p<0.0005) (Table 1; Figure 2), apparently independent of incidence rates. Secondary cases were younger than primary cases (median 13 years vs. 20 years; p<0.0005). Fewer secondary than primary cases had bloody diarrhea (54% vs. 66%; p = 0.02) (Table 2), but secondary cases with bloody diarrhea were younger than primary cases with bloody diarrhea (median 13 years vs. 26 years; p<0.03), perhaps reflecting lower thresholds for screening younger contacts. Secondary cases accounted for 12% of all HUS cases, and their likelihood of having HUS was similar to that of primary cases (p = 0.95) (Table 2). Mean time between onset in primary and secondary cases was 8 days (range 3–24 days); the longer times occurred when primary cases were symptomatic for >14 days. Child-to-child transmission accounted for 72% of secondary cases, child-to-adult for 19%, and adult-to-adult for 9%.
Most cases (1,787/2,228 [80%]) were sporadic (Table 1; Figure 2). Similar proportions of sporadic and outbreak cases (p = 0.89) had illness progressing to HUS. Of the 1,650 sporadic cases who were symptomatic, 158 (10%) were secondary cases (Table 2). Sporadic and outbreak secondary cases had the same risk for HUS (p = 0.97), but sporadic secondary cases were younger (median 9 years vs. 26 years; p<0.04), highlighting the need to prevent transmission within single households.
Outbreak cases constituted 441/2,228 (20%) cases, but proportions varied annually (range 13%–27%; p<0.0005) (Table 1; Figure 2). Of the 88 secondary cases in outbreaks, 57 (65%) lived in the same household as the associated primary case; the remainder were contacts either in institutions or in linked second households. The 441 outbreak cases comprised 104 separate outbreaks. Secondary cases were identified in 40 (42%) of the 95 outbreaks that occurred in Scotland, with an average ratio of secondary to primary cases of 1.3:1.
The reasons for high incidence rates of E. coli O157 in Scotland are undoubtedly complex and multifactorial. Influences affecting real incidence may include the relative population densities of livestock and humans and reliance on private water supplies (8).
Ascertainment of secondary cases in Scotland, which appeared to have a greater role in our study than may have been commonly assumed previously, may however be particularly affected by artifactual influences, such as more assiduous contact tracing resulting from heightened awareness, perhaps triggered by a combination of large outbreaks, a national task force, and enhanced surveillance (7,8). This possibility necessitates caution in extrapolating our findings on secondary case incidence to other countries. Such tracing and confirmation of infection is valuable in controlling household transmission as well as outbreaks, and for clinical management (10,11). Alternatively, some secondary cases will undoubtedly be missed, or misclassified as primary cases.
Because most secondary cases in Scotland are apparently sporadic, our findings also reinforce the need for low thresholds for suspecting infectious etiology in acute diarrhea (particularly if bloody), irrespective of (and without waiting to discover) whether cases are part of outbreaks (2,11). Patients need immediate advice about infection control in the home, accompanied by immediate stool sampling and monitoring (e.g., blood parameters), not just for primary or index cases but also for their contacts (9–11). We must continually raise professional and public awareness of secondary spread and measures needed to reduce it, and to ameliorate health outcomes (2,9,10). We should also maintain preventive strategies targeting the livestock-related risks strongly associated with sporadic infection (8,14,15).
We believe enhanced surveillance in Scotland provides uniquely valuable information, particularly about secondary transmission, because data derive from the entire population and are standardized and long term. They remove reliance on extrapolating from studies of outbreaks, subgroups, or other countries, which may use substantially different methods and settings. Our data also permit robust long-term analysis, which is central to identifying whether differences in incidence or epidemiology are real or artifactual, and whether those differences are meaningful for public health.
We strongly recommend increased efforts to prevent secondary transmission within individual households. This would reduce not only the overall health and social costs of E. coli O157 infection but also the number of, and distress to, HUS cases attributable to secondary spread.
Ms Locking is an epidemiologist at Health Protection Scotland, where she established the national VTEC Enhanced Surveillance System. Her work includes investigating verotoxin-producing E. coli outbreaks and using surveillance data on the etiology and outcomes of infection to identify and support health protection initiatives, particularly in rural settings.
We thank participating patients and their relatives and the following groups across Scotland: Health Protection Teams in National Health Service boards, environmental health officers, consultant microbiologists and diagnostic laboratory staff; general practitioners, Scottish Agricultural College, and previous and present personnel at HPS and Scottish E. coli O157/VTEC Reference Laboratory.
- Karmali MA, Steele BT, Petric M, Lim C. Sporadic cases of haemolytic-uraemic syndrome associated with faecal cytotoxin and cytotoxin-producing Escherichia coli in stools. Lancet. 1983;1:619–20.
- Tarr PI, Gordon CA, Chandler WL. Shiga-toxin–producing Escherichia coli and haemolytic uraemic syndrome. Lancet. 2005;365:1073–86.
- Tuttle J, Gomez T, Doyle MP, Wells JG, Zhao T, Tauxe RV, Lessons from a large outbreak of Escherichia coli O157:H7 infections: insights into the infectious dose and method of widespread contamination of hamburger patties. Epidemiol Infect. 1999;122:185–92.
- Parry SM, Salmon RL. Sporadic STEC O157 infection: secondary household transmission in Wales. Emerg Infect Dis. 1998;4:657–61.
- Michino H, Araki K, Minami S, Takaya S, Sakai N, Miyazaki M, Massive outbreak of Escherichia coli O157:H7 infection in schoolchildren in Sakai City, Japan, associated with consumption of white radish sprouts. Am J Epidemiol. 1999;150:787–96.
- Public Health Agency of Canada. Waterborne outbreak of gastroenteritis associated with a contaminated municipal water supply, Walkerton, Ontario, May–June 2000. Can Commun Dis Rep. 2000;26:170–3.
- Cowden JM, Ahmed S, Donaghy M, Riley A. Epidemiological investigation of the central Scotland outbreak of Escherichia coli O157 infection, November to December 1996. Epidemiol Infect. 2001;126:335–41.
- Scottish Executive Health Department/Food Standards Agency (Scotland). Report of the E. coli O157 Task Force. Edinburgh: The Stationery Office, 2001 Oct 24 [cited 2010 Jan 22]. http://www.food.gov.uk/news/newsarchive/2001/oct/ecolitask
- Seto EY, Soler JA, Colford JM Jr. Strategies to reduce person-to-person transmission during widespread Escherichia coli O157:H7 outbreak. Emerg Infect Dis. 2007;13:860–6.
- Werber D, Mason BW, Evans MR, Salmon RL. Preventing household transmission of Shiga toxin–producing Escherichia coli O157 infection: promptly separating siblings might be the key. Clin Infect Dis. 2008;46:1189–96.
- Belongia EA, Osterholm MT, Soler JT, Ammend DA, Braun JE, MacDonald KL. Transmission of Escherichia coli O157:H7 infection in Minnesota child day-care facilities. JAMA. 1993;269:883–8.
- Snedeker KG, Shaw DJ, Locking ME, Prescott RJ. Primary and secondary cases in E. coli O157 outbreaks: a statistical analysis. BMC Infect Dis. 2009;9:144.
- Pollock KGJ, Locking ME, Rae L. Enhanced surveillance of thrombotic microangiopathies in Scotland, 2003–2008. Health Protection Scotland Weekly Report. 2009;43:104–5 [serial on the Internet]. 2009 Mar [cited 2010 Jan 22]. http://www.documents.hps.scot.nhs.uk/ewr/pdf2009/0910.pdf
- Locking ME, O’Brien SJ, Reilly WJ, Wright EM, Campbell DM, Coia JE, Risk factors for sporadic cases of Escherichia coli O157 infection: the importance of contact with animal excreta. Epidemiol Infect. 2001;127:215–20.
- Innocent GT, Mellor DJ, McEwen SA, Reilly WJ, Smallwood J, Locking ME, Spatial and temporal epidemiology of sporadic human cases of Escherichia coli O157 in Scotland, 1996–1999. Epidemiol Infect. 2005;133:1033–41.
- Figure 1. Rates per 100,000 population of laboratory-confirmed culture-positive Escherichia coli O157 cases, by country, United Kingdom, 1984–2008. Data outside Scotland courtesy of Health Protection Agency London, and Public Health Agency...
- Figure 2. Secondary symptomatic or primary symptomatic laboratory-confirmed Escherichia coli O157 cases, by outbreak or sporadic occurence, Scotland, 1984–2008.
- Table 1. Selected characteristics and health outcomes of laboratory-confirmed Escherichia coli O157 cases, Scotland, 1999–2008
- Table 2. Selected characteristics and health outcomes of secondary or primary symptomatic laboratory-confirmed Escherichia coli O157 cases, Scotland, 1999–2008
Please use the form below to submit correspondence to the authors or contact them at the following address:
Mary E. Locking, Health Protection Scotland, Clifton House, Clifton Pl, Glasgow G3 7LN, Scotland, UK
Comment submitted successfully, thank you for your feedback.
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
- Page created: July 25, 2011
- Page last updated: July 25, 2011
- Page last reviewed: July 25, 2011
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)